Stay updated with breaking news from Interferon Pathway. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CANTON — St. Lawrence Health’s Clinical and Rural Health Research Department is currently conducting a TULIP (Treatment of Uncontrolled Lupus via the Interferon Pathway) clinical trial being sponsored by AstraZeneca.
Investegate announcements from AstraZeneca PLC, Saphnelo approved in EU for SLE
AstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite receiving standard therapy. Saphnelo is the first biologic for SLE approved in ...
AstraZeneca’s Saphnelo (anifrolumab) has been recommended for marketing authorisation in the European Union (EU) as an add-on therapy for the
A new post-hoc analysis of pooled data from the TULIP Phase III clinical trials being presented at the annual European Congress of Rheumatology (EULAR...